טוען...
Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation
BACKGROUND: Tofacitinib is a novel Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. In clinical trials, the most common adverse events observed were nasopharyngitis, upper respiratory tract infections, and zoster. JAKs are...
שמור ב:
| הוצא לאור ב: | Arthritis Res Ther |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8138978/ https://ncbi.nlm.nih.gov/pubmed/34020693 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-021-02509-8 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|